Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Association between the novel inflammatory marker white blood cell count-to-mean platelet volume ratio and metabolic syndrome: A cross-sectional study based on NHANES 2011-2020

Huang S., Wang Y., Wang Y., Miao Y.

Prospective Study with a reported sample of 4917 on Type 2 Diabetes, Chronic Inflammation, published in PLoS One (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
PLoS One (2026)
Reported sample size
4917
Source database
Europe PMC
PMID
41926362
PMCID
PMC13046166
DOI
10.1371/journal.pone.0344017

Abstract (original English)

Background Metabolic syndrome (MetS) is a chronic non-infective syndrome characterized by a set of vascular risk factors, including insulin resistance, hypertension, abdominal obesity, impaired glucose metabolism, and dyslipidaemia. This study aims to investigate the potential association between a novel inflammatory marker, the white blood cell count-to-mean platelet volume ratio (WMR), and MetS. By examining this association, we seek to provide data supporting the effective prevention of MetS through the improvement of inflammatory responses. Methods We conducted a cross-sectional study using data from adult participants in the National Health and Nutrition Examination Survey (NHANES) from 2011 to 2020. Comprehensive data on complete blood count parameters and MetS were collected. MetS was defined according to the Adult Treatment Program III of the National Cholesterol Education Program. The formula for calculating WMR is: WMR = white blood cell count (1000 cells/μl)/ mean platelet volume (fL). Participants were stratified into four quartile groups (Q1 to Q4) based on their WMR levels, and chi-square tests along with rank-sum tests were utilized to assess differences in variables. Spearman correlation analysis was employed to evaluate the association between WMR and risk factors linked to MetS and other clinical indicators. Logistic regression analysis and subgroup analysis w

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansInflammationLeukocyte CountNutrition SurveysRisk FactorsCross-Sectional StudiesAdultMiddle AgedFemaleMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research